October 2010
learning curve

The FDA’s decision on Bydureon was a shocker. We break down this decision and discuss why we view it as such a disappointment.

Download This Issue

Articles

from the editor

Kelly laments the FDA's latest disappointing decision and extends a personal...
quotable quotes

(S)he said what?!?
fingersticks

Imagine, a world with a cure...
test drive

Type 1s and GLP-1s? ...
conference pearls

Our top takeaways from the European Association for the Study of Diabetes...
trial watch

Resveratrol as a treatment for type 2 diabetes and obesity, a parental support system for parents whose children have type 1 diabetes, and more.
sum musings

Kerri Morrone Sparling reflects on the power of electronic health journaling to...
thinking like a pancreas

Are your basal insulin settings on your pump correct? Gary Scheiner provides his...
new now next

Bydureon and Lorqess denied regulatory approval in the US by the FDA, Pfizer and Biocon’s partnership for biosimilar insulins, and more.